Related Experiment Videos
MET expression in sporadic renal cell carcinomas.
Jong Sun Choi1, Mi-Kyung Kim, Jin Won Seo
1Department of Pathology, Cheil General Hospital, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Korea.
Journal of Korean Medical Science
|August 8, 2006
Summary
The MET proto-oncogene is highly expressed in papillary and collecting duct renal cell carcinoma (RCC), aiding in diagnosis. MET expression in clear cell RCC indicates aggressive features.
Area of Science:
- Oncology
- Molecular Pathology
- Urologic Pathology
Background:
- Germline mutations in the MET proto-oncogene are established markers for hereditary papillary renal cell carcinoma (RCC).
- The expression and clinical significance of MET protein in sporadic RCC remain underexplored.
Purpose of the Study:
- To investigate the expression patterns of MET protein in various subtypes of renal neoplasms.
- To determine the clinical significance of MET expression in sporadic renal cell carcinoma, particularly clear cell RCC.
Main Methods:
- Immunohistochemistry was employed to assess MET expression.
- The study analyzed 182 cases, including 145 RCCs, 25 urothelial carcinomas of the renal pelvis, and 12 oncocytomas.
Main Results:
- Diffuse and strong MET expression was observed in 90% of papillary RCC, all collecting duct carcinomas, and 92% of urothelial carcinomas of the renal pelvis.
- Clear cell RCC, chromophobe RCC, and oncocytomas showed negative or focal MET expression.
- In clear cell RCC, MET expression correlated with high nuclear grade, infiltrative growth, necrosis, papillary architecture, sarcomatoid features, pelvic/ureteral involvement, calyceal involvement, and lymphatic invasion.
Conclusions:
- Diffused and strong MET expression can help differentiate papillary RCC and collecting duct carcinoma from other RCC subtypes with tubular or papillary growth.
- MET expression in clear cell RCC may serve as a biomarker for aggressive clinicopathological features.